CART-WHEEL is building a registry for patients diagnosed with rare tumors or rare subtypes of common tumors.
People from all over the world are invited to submit information about their tumor to pool together records from many different people with the same tumor type. This will help to better understand these rare tumors and to help develop new treatments for them.

This project has been granted ethical approval by an internationally recognised Human Research Ethics Committee based at Royal Melbourne Hospital, Australia.

Health professionals can provide their patients with rare tumours, or with common tumor types (eg bowel, lung, prostate and breast cancer), who may have some information about the genes underlying their cancer (eg an inherited gene (eg BRCA1/2, MLH1) or alternatively, a gene important to their cancer's survival may have been identified (eg EGFR, PI3K, Her2) or patients belonging to a certain ethnicity or medical grouping may also benefit from closer study as a group. A full list of tumour groups is available. 

A patient or their proxy needs to register and log on (as the patient) and then proceed through the various screens, entering their data (it will be helpful for them to have information such as their histopathology report with them: they can enter and leave as the questionnaire as many times as they like in order to complete / update the form).

A Participant Information Brochure has been developed, a sample questionnaire can be viewed and a sample summary can be downloaded.

Professionals who are interested in accessing patient data (with details of pathology reports) or in finding patients for a particular clinical trial, please see the Research page.

Providing relevant, high quality and up-to-date information, MedConnect is a gateway to leading local and international medical news, research, events and resources to allow health care professionals to stay connected to the most important developments in medicine.

The other cancers page includes rarer tumours and features the latest news, research, drugs, podcasts, videos, articles, conferences and events.  

Users can sign up for free to receive daily news feeds and journal summaries about their specialist topic.

A searchable site of best practice guidelines and protocols for the prevention, diagnosis and treatment of diseases.

The  NGC's mission is to provide physicians and other health professionals and others an accessible mechanism for obtaining objective, detailed information on clinical practice guidelines and to further their dissemination, implementation, and use.

All of the criteria below must be met for a clinical practice guideline to be included in NGC:

• The clinical practice guideline contains systematically developed statements that include recommendations, strategies, or information that assists physicians and/or other health care practitioners and patients to make decisions about appropriate health care for specific clinical circumstances.
• The clinical practice guideline was produced under the auspices of medical specialty associations; relevant professional societies, public or private organizations, government agencies at the Federal, State, or local level; or health care organizations or plans. A clinical practice guideline developed and issued by an individual not officially sponsored or supported by one of the above types of organizations does not meet the inclusion criteria for NGC.
• Corroborating documentation can be produced and verified that a systematic literature search and review of existing scientific evidence published in peer reviewed journals was performed during the guideline development. A guideline is not excluded from NGC if corroborating documentation can be produced and verified detailing specific gaps in scientific evidence for some of the guideline's recommendations.
• The full text guideline is available upon request in print or electronic format (for free or for a fee), in the English language. The guideline is current and the most recent version produced. Documented evidence can be produced or verified that the guideline was developed, reviewed, or revised within the last five years.

A full range of guidelines and resources relating to rare tumours and cancers. including:

• information about prevention, genetics and causes
• screening and testing unformation about methods of cancer detection including new imaging technologies, tumor markers, and biopsy procedures
• Information about treatment, including surgery, chemotherapy, radiation therapy, immunotherapy, and vaccine therapy
• statistics related to cancer incidence, mortality, and survival
• research
• information and current news about clinical trials and trial-related data

Researchers at Memorial Sloan-Kettering Cancer Center have pioneered the use of computerized devices to help patients and their physicians decide among the major treatment choices for several cancers.

Rather than relying on general risk groups of patient populations who share similar characteristics, our prediction tools provide specific information.

Currently available tools for rare cancers include:

A moderated online patient networking forum where patients with rare cancers & their caregivers can share support; treatment information and personal experiences.

Comprehenisve oncologist approved information about endocrine tumours. A guide is also available for:

• Thyroid Cancer
• Parathyroid Cancer
• Adrenal Gland Tumor
• Pituitary Gland Tumor
• Islet Cell Tumor
• Multiple Endocrine Neoplasia Type 1
• Multiple Endocrine Neoplasia Type 2
  

Each guide provides information on:

• Overview
• Medical Illustrations
• Risk Factors
• Prevention
• Symptoms
• Diagnosis
• Staging With Illustrations
• Treatment
• Clinical Trials Resources
• Side Effects, After Treatment
• Current Research
• Questions to Ask the Doctor
• Patient Information Resources

Information about the genetic risk of thyroid cancer and methods of preventing the development of the disease.

The deCODEme Complete Scan and the deCODEme Cancer Scan identify these variants and provide an interpretation of the associated risk for the development of thyroid cancer for individuals of European descent. At this time risk information is not available for other ethnicities.

A range of downloadable clinical practice guidelines developed and endorsed by NCCN for endocrine cancers, including:

A library of downloadable clinical practice guidelines developed in the UK and internationally relating to the diagnosis, treatment and management of endocrine cancers, including:

• Thyroid
• Parathyroid
• Pituitary
• Adrenals

Comprehensive information regarding the following endocrine tumours:

• Carcinoid Tumors
• Pancreatic Cancer
• Parathyroid Cancer
• Thyroid Cancer
• Pituitary Cancer
  

A list of links to recent referreed journal publications regarding pancreatic cancer and other endocrine and neuroendocrine tumours.

A range of clinical practice tools and resources including guidelines, slides and patient information regarding gastrointestinal and colorectal cancers.

ASCO's Gastrointestinal Cancer Portal offers gastrointestinal cancer specific resources including the latest information from:

• ASCO's Virtual Meeting
• The Journal of Clinical Oncology
• Gastrointestinal Cancer Clinical Practice Guidelines
• Meeting abstracts
• Educational Book manuscripts
• ASCO Daily News

Website listing gastrointestinal cancer trials open in Australia as well as relevant events.

The AASTN Inc. Education and Professional Development Subcommittee has developed a series of Patient Education Pamphlets for use by Stomal Therapy Nurses in the education of ostomates and others.

Brochures include:

• Caring for your colostomy
• Managing constipation
• Caring for your stoma
• Caring for your ileostomy
• Caring for your urostomy

Most brochures are available in multilingual translations and can be downloaded the Royal District Nursing Service website.

Professional and educational body for Stomal Therapy nurses.

Membership includes access to member site, CPD opportunities, conference attendance and patient information.

ACSA represents, at a national level, the interests of all 22 regional Stoma Associations in Australia.

A list of patient support groups is also available on the site.

Bowel Cancer Australia is national charity with a mission to decrease the impact of bowel cancer and gastrointestinal diseases in our society through awareness, education, support and research.

Bowel Cancer Australia aims to achieve this by -

• funding cutting edge research into bowel cancer and gastrointestinal diseases;
• establishing Australia’s inaugural endowed Chair in Bowel Cancer Research and associated Centre of Excellence in Gastrointestinal Research;
• implementing awareness campaigns and education programs in conjunction with gastrointestinal specialists to reduce the incidence of bowel cancer and gastrointestinal diseases in the workplace and community;
• encouraging participation by Australians in appropriate screening for bowel cancer in accordance with the National Health and Medical Research Council’s (NHMRC) guidelines; and
• providing a support network for patients, their families and carers, including a nurse and nutritionist advisory service.

Comprehenisve oncologist approved information about gastrointestinal cancers, including:

• Stomach Cancer
• Pancreatic Cancer
• Liver Cancer
• Small Bowel Cancer
• Gastrointestinal Stromal Tumor - GIST
• Gallbladder Cancer
• Colorectal Cancer
• Bile Duct Cancer
• Appendix Cancer
• Anal Cancer

Each guide provides information on:

• Overview
• Medical Illustrations
• Risk Factors
• Prevention
• Symptoms
• Diagnosis
• Staging With Illustrations
• Treatment
• Clinical Trials Resources
• Side Effects, After Treatment
• Current Research
• Questions to Ask the Doctor
• Patient Information Resources

The Gastrointestinal Group is open to gastroenterologists, surgeons, medical oncologists, radiation oncologists, other medical specialists, nurses, stoma care providers, researchers and other health care professionals with an interest in the management of both colorectal and upper gastrointestinal malignancies.

The aim of the group is to promote education of health care professionals and the public on this area of oncology.  We also aim to provide a role in public health advocacy (particularly with regard to screening for colorectal cancer) and best practice guideline development.

The group has close links with the Australasian Gastrointestinal Trials Group (AGITG) that is predominantly involved in the conduct, organisation and development of multi-centre gastrointestinal oncology clinical trials.

Information about the genetic risk of pancreatic cancer and methods of preventing the development of the disease.

The deCODEme Complete Scan identifies the four common genetic variants mentioned above and uses them to provide customers of European descent with a personalized interpretation of their genetic risk for developing pancreatic cancer.

At present, the necessary scientific information to interpret the genetic risk for women of other ethnicities is not available. This information will be added as soon as it becomes available and we are assured of its quality.

This primary care upper gastrointestinal module includes resources and information specific to upper GI tumours including cancer of the oesophagus, stomach, liver, pancreas, gall bladder, bile ducts; treatments and side effect management, clincial tools, an opioid conversion calculator and safe handling of cytotoxics.

Free registration is required to access the site.

Information about the risks, symptoms, diagnosis and treatment of the following gastrointestinal cancers:

• Anal Cancer
• Bile Duct Cancer
• Carcinoid Cancer
• Gallbladder Cancer
• Liver Cancer
• Oesophageal Cancer
• Pancreatic Cancer
• Small Intestine Cancer
• Stomach (Gastric) Cancer

The ASCO Gastrointestinal Cancers MOC Module consists of 25 multiple-choice questions which include patient case information, educational links and answer rationales. This activity is a tool for self-assessment of medical knowledge as it relates to gastrointestinal cancers.

Upon completion of this educational activity, participants will be able to:

• Identify knowledge and practice gaps relating to gastrointestinal cancers
• Apply knowledge learned toward an enhanced ability to identify gastrointestinal cancer risks and recommend effective interventions for individual patients
• Demonstrate participation in life-long learning and enhancement of competence.

Consumer targeted overview of haematological cancers including:

• Liver cancer 
• Pancreatic cancer 
• Stomach cancer 

Information is provided regarding risk factors, signs and symptoms, diagnosis, treatment and links to a patient resource centre.

HemOnc Today strives to be the global, definitive information source for oncology and hematology professionals by delivering timely, accurate, authoritative and balanced reports on clinical issues, socioeconomic topics and industry developments relating to gastrointestinal cancers, as well as presenting clinically relevant information on medical therapies for the benefit of the patient.

Downloadable clinical practice guidelines developed and endorsed by NCCN for breast cancers, including:

• Anal Carcinoma
• Esophageal Cancer
• Gastric Cancer
• Hepatobiliary Cancers
• Colon Cancer
• Rectal Cancer
• Pancreatic Adenocarcinoma

A library of downloadable clinical practice guidelines developed in the UK and internationally relating to the diagnosis, treatment and management of Lower Gastrointestinal and colorectal cancers, including:

• Small bowel
• Colon
• Rectum
• Anus

A library of downloadable clinical practice guidelines developed in the UK and internationally relating to the diagnosis, treatment and management of Upper Gastrointestinal cancers, including:

• Oesophagus
• Stomach
• Gastrointestinal Stromal Tumours
• Liver
• Bile duct
• Pancreas
• Gall bladder

Comprehensive information regarding the following Gastrointestinal Cancers:

• Colorectal Cancer
• Gallbladder Cancer
• Liver Cancer (Childhood)
• Liver Cancer (Hepatoma
• Pancreatic Cancer
• Gastric Cancer
• Small Intestine Cancers

Information on adenocarcinoma of the pancreas, which comprises 90-95% of all pancreatic cancer, is included in this tool. Other types of pancreatic cancers (such as islet cell tumors, lymphomas, or tumors that have spread from other areas) are not addressed in this tool.

The Pancreatic Cancer Profiler treatment decision support tool helps you understand how your diagnosis, test results, and medical history affect your treatment options. Your free Treatment Options Report will include descriptions of treatments, side effects, and questions to ask your doctor…customized for your unique diagnosis.

The aim of this program is to provide information and support for all affected by pancreatic cancer.

The information provided here is latest best practice in Australia. It is designed to help you understand what having pancreatic cancer means and to support the information provided to you by your doctor and health team. It aims to help you find the words to discuss with your doctor your individual situation.

The information and support services have been developed in conjunction with medical and health professionals in the New South Wales Pancreatic Cancer Network.

This patient management framework is a guide to the optimal care management of patients with Oesophagogastric Cancer. It is intended to improve patient outcomes by facilitating consistent care based on evidence and best practice and sets out the key requirements for the provision of optimal care which need to be considered at each step of the care pathway.

In contrast to clinical practice guidelines that guide appropriate practice and decision making, the patient management frameworks provide a guide to the patient journey to ensure patients with cancer and their families receive optimal care and support.

This patient management framework is a guide to the optimal care management of patients with Pancreatic Cancer. It is intended to improve patient outcomes by facilitating consistent care based on evidence and best practice and sets out the key requirements for the provision of optimal care which need to be considered at each step of the care pathway.

In contrast to clinical practice guidelines that guide appropriate practice and decision making, the patient management frameworks provide a guide to the patient journey to ensure patients with cancer and their families receive optimal care and support.

Almost a third of men who experience testicular cancer develop symptoms of an anxiety disorder, and is more likely to occur in younger men. This fact sheet provides information to assist you to be aware of the signs and symptoms of anxiety disorders and depression and to know where and when to seek help.

Andrology Australia is committed to providing information to health professionals to improve understanding of male reproductive health disorders, including prostate and testicular cancer. The purpose of the Andrology Australia health professional section is to provide on-line access for health professionals providing care to men with reproductive health issues. This section contains journal articles, evidence-based information, clinical guidelines, position statements and online activities relating to prostate cancer and testicular cancer .

The website also contains evidence based information about male reproductive cancers for consumers from the NHMRC‘s Clinical Practice Guidelines with comment and suggestions by the Urological Society of Australasia and the Prostate Cancer Foundation of Australia including prostate cancer fact sheets about localised prostate cancer and advanced prostate cancer;as well as information about testicular cancer treatments and issues including self examination, diagnosis and sperm storage.

Professionals can stay up to date with all the latest treatments and opinions by signing up for the new Andrology Australia email newsletter, The Healthy Male: http://www.andrologyaustralia.org/subscription.asp?pageCode=SUBSCRIBE

All resources can be order via Andrology Australia website www.andrologyaustralia.org

A range of clinical practice tools and resources including guidelines, slides and patient information regarding genitourinary cancers.

ASCO's Genitourinary Cancer Portal offers genitourinary cancer specific resources including the latest information from:

• ASCO's Virtual Meeting
• The Journal of Clinical Oncology
• Gentitourinary Cancer Clinical Practice Guidelines
• Meeting abstracts
• Educational Book manuscripts
• ASCO Daily News.

Consumer targeted overview of bladder and genitorurinary cancers including information regarding risk factors, signs and symptoms, diagnosis, treatment and links to a patient resource centre.

Comprehenisve oncologist approved information about genitourinary cancers, including:

• Germ Cell Tumor - Childhood
• Kidney Cancer
• Prostate Cancer
• Testicular Cancer
• Uterine Cancer
• Penile Cancer

Each guide provides information on:

• Overview
• Medical Illustrations
• Risk Factors
• Prevention
• Symptoms
• Diagnosis
• Staging With Illustrations
• Treatment
• Clinical Trials Resources
• Side Effects, After Treatment
• Current Research
• Questions to Ask the Doctor
• Patient Information Resources

The Urologic Oncology Group provides a national multidisciplinary forum for clinicians and researchers involved across the spectrum of urologic malignancies to come together to discuss initiatives in treatment and management and to develop collaborative basic and clinical research programs. The group continues to aim to be inclusive and welcomes anyone with an interest in research, management or treatment of these cancers.

The management of urologic cancers has changed rapidly over recent years as we develop a greater understanding of the biology of these diseases. New therapeutics are available for kidney and prostate cancer and treatment for bladder cancer is also evolving. Even in testicular cancer, where outcomes are already excellent, new opportunities for collaboration and improvement of care continue to arise. The optimal care of all patients with urologic malignancies is best performed in the context of a multidisciplinary group comprising urologists, medical oncologists, radiation oncologists, nurses, pathologists, palliative physicians, and many other disciplines within medical and allied health.

In the past, many of these groups did not ever see patients with some types of urologic cancers; now, it is increasingly recognised that they all have very important parts to play.

Consumers are playing an ever increasing and important role in setting priorities for research and use of public funds.

Information about the genetic risk of testicular cancer and methods of preventing the development of the disease.

The deCODEme Genetic Scan identifies these genetic variants and uses them to provide male customers of European descent with a personalized interpretation of their genetic risk for developing testicular cancer.

At present, the necessary scientific information to interpret the genetic risk for men of other ethnicities is not available. This information will be added as soon as it becomes available and we are assured of its quality.

The EAU represents the leading authority within Europe on urological practice, research and education. The EAU delivers training, stimulates research and broadcasts information. The EAU’s scientific publications encourage discussion and its expert recommendations guide urologists in their every-day practice.

The website contains information including upcoming events and educational opportunities, guidelines, latest research and publications, urological nursing, CME activities and members only sections.

The ASCO Genitourinary Cancers MOC Module consists of 25 multiple-choice questions which include patient case information, educational links and answer rationales. This activity is a tool for self-assessment of medical knowledge as it relates to genitourinary cancers.

Upon completion of this educational activity, participants will be able to:

• Identify knowledge and practice gaps relating to genitourinary cancers
• Apply knowledge learned toward an enhanced ability to identify genitourinary cancer risks and recommend effective interventions for individual patients
• Demonstrate participation in life-long learning and enhancement of competence.

Treatment decision tools to help patients make an informed decision about their treatment for the following cancers:

• Bladder Cancer
• Kidney Cancer
• Testicular Cancer

Using these tools, patients can access a detailed analysis of their specific condition, uncover a statistical breakdown of treatment types, and pinpoint the exact topics to discuss with their doctor.

HemOnc Today strives to be the global, definitive information source for oncology and hematology professionals by delivering timely, accurate, authoritative and balanced reports on clinical issues, socioeconomic topics and industry developments relating to Genitourinary cancers, as well as presenting clinically relevant information on medical therapies for the benefit of the patient.

Four challenging case studies moderated by Michael B. Atkins, MD and discussed by eleven national experts in renal cancer.

Learning Objective
Discuss considerations, assessment and treatment options, and recommended treatment strategies for four representative cases of renal cell cancer.

The monograph is also available.

A library of downloadable clinical practice guidelines developed in the UK and internationally relating to the diagnosis, treatment and management of urological cancers, including:

• Kidney
• Bladder
• Ureter and renal pelvis
• Prostate
• Penis
• Testis
• Urethra

Comprehensive information regarding the following urological cancers:

• Urethral Cancer
• Bladder Cancer
• Testicular Cancer
• Penile Cancer
• Kidney Cancer
• Adrenal Cancer
• Anal Cancer

A/Professor Mark Frydenberg discusses prostate cancer testing, management and treatment and the importance of the GPs role in the diagnosis and treatment of testicular cancer.

The audio file can be downloaded as an mp3 (10MB).

Information regarding the causes, prevention, early detection screening, diagnosis, treatment and effects of testicular cancer.

Developed with a medical advisory board of leading testicular and germ cell cancer experts, this website provides links to a wide range of up-to-date resources, information and activities regarding testicular and germ cell cancers, their symptoms, diagnosis and treatment; relevant to both health professionals and consumers.

• Cancer of the uterus
• Cancer of the vagina
• Cancer of the vulva
• Cervical cancer
• Ovarian cancer
• Ovarian germ cell tumours

Putting research into context, Clinical Update - Ovarian Cancer is produced by the National Breast Cancer and Ovarian Cancer Centre (NBOCC) as a service for health professionals, delivering timely expert comment on relevant journal articles direct to your email inbox. A brief abstract summarises key findings from a recent journal article, while commentary from an expert reviewer places the study outcomes into context for the Australian healthcare system.

Guidelines developed for health professionals about familial aspects of both breast and ovarian cancer. The aim of the guidelines is to help health professionals determine a woman‘s risk of developing breast or ovarian cancer based on her family history.

The Alliance consists of five partner organizations, brought together by their capabilities and experience in global cervical cancer prevention:

• EngenderHealth
• IAEA/PACT (International Atomic Energy Agency's Programme of Action for Cancer Therapy)
• IARC (International Agency for Research on Cancer)
• Jhpiego
• PAHO (Pan American Health Organization)
• Partners in Health
• PATH, Alliance coordinating agency
• UICC (International Union Against Cancer)

A broad range of documents and resources are available for download from the website, many in English, Spanish and French. Publications regarding cervical cancer prevention include:

• Special Features
• Fact Sheets
• Cervical Cancer Prevention Issues in Depth Series
• Presentations
• Planning Guides
• Training Materials
• Technical Reports
• Conference Proceedings
• Journal Articles

A guide to assist general practitioners provide appropriate referral paths for women with symptoms of ovarian cancer.

ASCO's Gynaecological Cancer Portal offers gynaecological cancer specific resources including the latest information from:

• ASCO's Virtual Meeting
• The Journal of Clinical Oncology
• Gynaecological Cancer Clinical Practice Guidelines
• Meeting abstracts
• Educational Book manuscripts
• ASCO Daily News.

The information in this guide is intended to assist general practitioners assess if a woman with persistent, unexplained symptoms may have ovarian cancer.

The guide is based on the clinical practice guidelines for the management of women with epithelial ovarian cancer.

Website listing gynaeoncology trials and events in Australia and New Zealand

National Breast and Ovarian Cancer Centre’s research, reviews and data reports regarding ovarian cancer including:

Ovarian cancer in Australia, an overview 2010, Publication date: February 2010

Report to the Nation - Ovarian Cancer 2010, Publication date: February 2010

Ovarian Cancer in Australia, an overview 2006, Publication date: November 2006

National Data Strategy for Breast and Ovarian Cancer, Publication date: February 2008

Updated from the 2004 guidelines, the Best Clinical Practice Gynaecological Cancer Guidelines 2009 includes information regarding the disease sites, pathology and clinical issues including clinical trials, familial aspects of gynaecological cancer, lymphoedema, palliative care, psychosocial care and vaginal stenosis.

The National Centre for Gynaecological Cancers aims to increase awareness and education about gynaecological cancers for medical and allied health professionals to improve the diagnosis, treatment and care of women affected by these cancers.

The Centre has collated a suite of consumer information resources on gynaecological cancers which provides quality and reliable information relating to the prevention, symptoms, diagnosis, treatment, and psychosocial care of gynaecological cancers in Australia, including:

• Cervical cancer consumer information sheets
• Endometrial cancer consumer information sheets
• Fallopian tube cancer consumer information sheets
• Gestational trophoblastic disease consumer information sheets
• Ovarian cancer consumer information
• Uterine sarcoma consumer information sheets
• Vaginal cancer consumer information sheets
• Vulval cancer consumer information sheets

There is also a suite of Useful Information brochures for consumers, containing information about:

• What is cancer? (PDF 429KB)
• Coping with your diagnosis. (PDF 479KB)
• Participating in clinical trials. (PDF 265KB)
• Managing pain. (PDF 742KB)
• Question checklist. (PDF 253KB)
• Survivorship and ongoing support. (PDF 964KB)
• Palliative care. (PDF 405KB)
• End of life issues. (PDF 398KB)
• Practical and financial support. (PDF 335KB)
• Other resources. (PDF 415KB)
• Glossary. (PDF 966KB) 

Information for people with gyanecological cancers and their families and friends; including information and downloadable PDF brochures regarding:

Comprehenisve oncologist approved information about urological cancers, including:

• Cervical Cancer
• Fallopian Tube Cancer
• Ovarian Cancer
• Uterine Cancer
• Vaginal Cancer
• Vulvar Cancer

Each guide provides information on:

• Overview
• Medical Illustrations
• Risk Factors
• Prevention
• Symptoms
• Diagnosis
• Staging With Illustrations
• Treatment
• Clinical Trials Resources
• Side Effects, After Treatment
• Current Research
• Questions to Ask the Doctor
• Patient Information Resources

Developed as part of the Gynaecological Cancer Society‘s Information and Education Programme, the site provides information that caters to the needs of professionals in a wide range of specialty areas. This information is holistic, authoritative and cancer specific, covering the full range of gynaecological cancers. Printable patient fact sheets are also available on the site.

Information about the latest research into the screening, risk factors and incidence of cervical cancer, with links to evidence based articles and reports.

The clinical practice guidelines for the management of women with epithelial ovarian cancer aim to:

• improve the quality of healthcare for women
• educate those involved in the care of women with epithelial ovarian cancer
• assist the decision-making process by women with epithelial ovarian cancer and their doctors
• and facilitate the optimal treatment of women with epithelial ovarian cancer.

Available as a single PDF file. Hard copies can be ordered.

The Australia New Zealand Gynaecological Oncology Group (ANZGOG) functions as the Gynaecological Oncology group of COSA.  ANZGOG is an interdisciplinary group with membership open to anyone in Australia and New Zealand with an interest in the management of women with gynaecological malignancies, including medical, gynaecological and radiation oncologists, research nurses, pathologists, epidemiologists and others.

ANZGOG conducts research through clinical trials to improve the prevention, early detection and treatment of women with gynaecological cancers. Our current research portfolio consists of clinical trials in ovarian, endometrial and cervical cancers.

ANZGOG works with various other groups and organisations outside of COSA including the Australian Society of Gynaecological Oncologists (ASGO), the Psycho-Oncology Cooperative Group (PoCoG), the TransTasman Radiation Oncology Group and internationally, with the Gynaecological Cancer Intergroup (GCIG) and the Gynaecological Oncology Group - USA (GOG).  Our international collaboration has allowed ANZGOG to take a leading role in a number of global clinical trials.

Information about the genetic risk of ovarian cancer and methods of preventing the development of the disease.

The deCODEme Complete Scan identifies this genetic variant in the 9p22.2 region and uses it to provide female customers of European descent with a personalized interpretation of their genetic risk for developing ovarian cancer.

At present, the necessary scientific information to interpret the genetic risk for women of other ethnicities is not available. This information will be added as soon as it becomes available and we are assured of its quality.

This case study recounts the experience of Jane, a 36-year-old female diagnosed with ovarian cancer. This case study aims to facilitate the development of competencies that reflect the role of the Specialist Cancer Nurse (SCN) in preventing, assessing and managing disease and treatment-related care for people affected by ovarian cancer across the cancer journey.

The case study contains four sections:

• Find the condition early
• Have the best treatment and support during active treatment
• Have the best treatment and support between and after active treatment
• Have the best care at the end of life.

This primary care module content area includes resources and information specific to gynaecological cancers; treatments and side effect management, clincial tools, an opioid conversion calculator and safe handling of cytotoxics.

Free registration is required to access the site.

Consumer targeted overview of haematological cancers including:

• Cervical cancer 
• Ovarian cancer
• Uterine (endometrial) cancer 

Information is provided regarding risk factors, signs and symptoms, diagnosis, treatment and links to a patient resource centre.

HemOnc Today strives to be the global, definitive information source for oncology and hematology professionals by delivering timely, accurate, authoritative and balanced reports on clinical issues, socioeconomic topics and industry developments relating to Gynecologic Cancers, as well as presenting clinically relevant information on medical therapies for the benefit of the patient.

Nurses are in a key position to promote cervical screening to all women.

The International Society of Nurses in Cancer Care is committed to supporting strategies that will reduce the incidence, morbidity, and mortality of cervical cancer.

This position statement contains recommendations that demonstrate the Society's support for strategies that promote equity of access and ensure ethical considerations are intrinsic in all screening/ prevention endeavours.

The National Centre for Gynaecological Cancers is an Australian Government initiative to improve outcomes for women affected by gynaecological cancers and their families and caregivers.

It has been established by Cancer Australia. The Centre provides national leadership to improve outcomes for women with gynaecological cancers and increase awareness and education about gynaecological cancers for medical and allied health professionals, including an interactive psychosexual training module for health professionals to address the psychosexual care of women affected by gynaecological cancers

The National Cervical Screening Program aims to reduce morbidity and deaths from cervical cancer, in a cost-effective manner through an organised approach to cervical screening. The Program encourages women in the target population to have regular Pap smears.

The Program promotes routine screening with Pap smears every two years for women between the ages of 18 (or two years after first sexual intercourse, whichever is later) and 69 years.

This Framework is designed to help guide services in the delivery of quality multidisciplinary gynaecological cancer care and was developed in close consultation with a project working group comprising representation from key professional groups, and a consumer reference group

Downloadable clinical practice guidelines developed and endorsed by NCCN for the early detection of cervical cancer.

Downloadable clinical practice guidelines developed and endorsed by NCCN for gynaecological cancers, including:

• Cervical Cancer
• Ovarian Cancer
• Uterine Neoplasms 

A full range of guidelines and resources relating to gynaecological cancers. including:

• Cervical Cancer
• Endometrial Cancer
• Ovarian Cancer
• Uterine Cancer, Endometrial
• Uterine Sarcoma
• Vaginal Cancer
• Vulvar Cancer
• Women's Cancers

Information provided includes:

• information about prevention, genetics and causes
• screening and testing unformation about methods of cancer detection including new imaging technologies, tumor markers, and biopsy procedures
• Information about treatment, including surgery, chemotherapy, radiation therapy, immunotherapy, and vaccine therapy
• statistics related to cancer incidence, mortality, and survival
• research
• information and current news about clinical trials and trial-related data

A library of downloadable clinical practice guidelines developed in the UK and internationally relating to the diagnosis, treatment and management of gynaecological cancers, including:

• Ovary
• Cervix
• Uterine body
• Vagina
• Vulva
• Fallopian tube

Comprehensive information regarding the following Gynaecological Cancers:

• Cervical Cancer
• Endometrial and Uterine Cancer
• Fallopian Tube Cancer
• Gestational Trophoblastic Disease and Choriocarcinoma
• Ovarian Cancer
• Vaginal Cancer
• Vulvar Cancer
  
  
  
  

• Strategies for the Management of Platinum-Resistant, Recurrent Ovarian Cancer   

Please note: activities have an expiry date

Ovarian Cancer Australia is the country’s leading organisation for ovarian cancer awareness and support. We are a national not-for-profit organisation founded in 2001 by people directly affected by ovarian cancer.

Their mission is to:

Support women with ovarian cancer, their families, friends and carers with compassionate support programs and practical resources.
Educate communities and individuals about the disease and increase their awareness of symptoms and the latest treatment, research and clinical trials from across Australia.
Advocate to improve outcomes, treatment and quality of life for women with ovarian cancer.

Ovarian Cancer Australia is a key part of an international alliance of ovarian cancer organisations who work to raise awareness of ovarian cancer on a global scale including:

• Ovarian Cancer Action (UK)
• Ovacome (UK)
• Ovarian Cancer National Alliance (USA)
• Ovarian Cancer Canada
• New Zealand Gynaecological Association

A range of documents developed by a UK based cancer network regarding pathways for the treatment of the following gynaecological cancers:

• The Management of Cervical Cancer - A Pathway of Care

• The Management of Endometrial Cancer - A Pathway of Care
  

• The Management of Ovarian Cancer - A Pathway of Care
  

• The Management of Vaginal and Vulval Cancer - A Pathway of Care
  

• Follow Up for Gynaecological Cancers

This patient management framework is a guide to the optimal care management of patients with Ovarian Cancer. It is intended to improve patient outcomes by facilitating consistent care based on evidence and best practice and sets out the key requirements for the provision of optimal care which need to be considered at each step of the care pathway.

In contrast to clinical practice guidelines that guide appropriate practice and decision making, the patient management frameworks provide a guide to the patient journey to ensure patients with cancer and their families receive optimal care and support.

Information about radiation therapy treatment options for patients with gynecologic cancers, including downloadable PDF fact sheets including information about possible side effects of treatment.

Gynaecological Oncologists are specialists in obstetrics and gynaecology, awarded the FRANZCOG, who have completed a formal three year training program in gynaecological cancer care and have passed the examination for the CGO.

The CGO Handbook contains essential information about the RANZCOG CGO training program and should be read in conjunction with the Subspecialty Policies and Procedures Manual which contains essential information about the RANZCOG Subspecialties training programs.

Ovarian cancer is the fourth most common cause of cancer deaths among women. It has a poor prognosis, with average five year survival rate of around 30%.

The traditional view has been that the poor prognosis of most patients with ovarian cancer is due to patients presenting late due to the absence of early symptoms. Recent research suggests that this view is wrong, and that most women with ovarian cancer do experience symptoms, which they usually report to their GPs.³ This may allow doctors to make an earlier diagnosis. It is hoped that by raising awareness of the symptoms of ovarian cancer among patients and doctors some women may be diagnosed earlier and lives may be saved.

An online information resource regarding cervical cancer for health professionals working in developing or low resource areas.

Links are included to their library of resources including:

• 10 Key Findings and Recommendations for Effective Cervical Cancer Screening and Treatment Programs
• Cervical Cancer Prevention Initiatives at PATH
• Cervical cancer prevention and the Millennium Development Goals (2008)
• Comprehensive Cervical Cancer Control: A guide to essential practice (2006)
• Global Guidance for Cervical Cancer Prevention and Control (2009)
• Progress in preventing cervical cancer: Updated evidence on vaccination and screening

To further increase the reach and effectiveness of the screening programme for cervical cancer, the NHS Cancer Screening Programmes has issued guidance on cervical screening: this module is based on the guidance. The module offers practical advice, but is not meant to replace clinical judgment. The module encourages healthcare professionals to take into account patients' values and preferences when caring for them.

The National Cervical Screening Program aims to reduce incidence and death from cervical cancer, in a cost-effective manner, through a more organised approach to cervical screening.

The Program promotes routine screening with Pap smears every two years for women between the ages of 18 (or two years after first sexual intercourse, whichever is later) and 69 years.

Resources for health professionals are included on the site, including the Screening Essentials Kit and Human Papillomavirus Vaccines for Australians: Information for GPs and Immunisation Providers.

Developed by National Centre for Gynaecological Cancers, Cancer Australia in conjuction with QUT Institute of Health and Biomedical Innovation, The Psychosexual Care of Women Affected by Gynaecological Cancers learning modules will help all health professionals develop the knowledge and skills to support women and their partners experiencing psychosexual concerns following gynaecological cancer.

Based around a Framework for the development of an interactive training module for health professionals to address the psychosexual care of women affected by gynaecological cancers, the modules comprise six components addressing the following topics:

• Module 1: Understanding sexuality
• Module 2: Understanding the experience of the Psychosexual Effects of Gynaecological Cancer for women and their partners
• Module 3: Enquiring and responding to the psychosexual sequelae of gynaecological cancers
• Module 4: Understanding psychosexual sequelae: Pathophysiological,Psychosocial , and Cultural Aspects
• Module 5: Undertaking a comprehensive sexual health assessment
• Module 6: Evidence based approaches to treatment of psychosexual sequelae of gynaecological cancers

The modules incorporate interactive learning activities and video vignettes to provide authentic learning materials based around the experiences of women treated for gynaecological cancers. The modules also promote critical reflection on personal attitudes and beliefs regarding psychosexual care.

In addition, an accompanying guide helps users select specific content and activities to meet their individual learning objectives. In addition, supporting resources, including psychosexual assessment and referral tools as well as information about psychosexual support, are included throughout.

This resource can be used for self directed learning by individuals, or by educators in both clinical and academic settings as part of a facilitated learning program. The program can be tailored to the needs of professionals from various disciplines working in a variety of healthcare settings, including general practitioners, nurses, allied health professionals and oncologists.

• Leukaemias
• Lymphomas
• Multiple Myelomas

ASCO's Haematological Cancer Portal offers haematological cancer specific resources including the latest information from:

• ASCO's Virtual Meeting
• The Journal of Clinical Oncology
• Haematological Cancer Clinical Practice Guidelines
• Meeting abstracts
• Educational Book manuscripts
• ASCO Daily News.

A range of clinical practice tools and resources including guidelines, slides and patient information regarding hematological malignancies, including a patient guide to multiple myeloma.

Website listing leukaemia and lymphoma trials in Australia as well as relevant events.

loodLine was launched in December of 1995 at the American Society of Hematology Annual Meeting. Initially, it was a reference site containing links to important hematology sites and resources on the Internet. Over the years, the site has gone through many major revisions with the aim of placing more emphasis on the publication of original content and improving the site's editorial focus and scientific validity.

Access is available to:

• PDF issues of Grand Rounds in Haematology
• PDF issues of BloodLine Reviews
• CME activities
• Image Atlas

Bloodline, a publication of Carden Jennings Publishing Co., Ltd., is dedicated to furthering and enhancing the fields of hematology and oncology through the presentation of knowledge in the following manners:

• the publication of original clinical and laboratory research.
• the creation of comprehensive reference works that are continuously useful to clinicians and researchers in the blood sciences.
• the creation and dissemination of educational materials.
• the publication of new and emerging science presented at conferences worldwide.
• the archiving of a comprehensive library of third-party resources of ongoing interest to clinicians and researchers.
• the maintenance of a means for clinicians and researchers to interact.
• the presentation of material in an easy-to-use networked format.

Information for people with gyanecological cancers and their families and friends; including information and downloadable PDF brochures regarding:

Comprehenisve oncologist approved information about haematological cancers, including:

• Leukemia - Acute Lymphoblastic - ALL - Childhood
• Leukemia - Acute Lymphocytic - ALL
• Leukemia - Acute Myeloid - AML
• Leukemia - Acute Myeloid - AML - Childhood
• Leukemia - B-Cell
• Leukemia - Chronic Lymphocytic - CLL
• Leukemia - Chronic Myeloid - CML
• Leukemia - Eosinophilic
• Leukemia - T-Cell
• Lymphoma - Hodgkin
• Lymphoma - Hodgkin - Childhood
• Lymphoma - Non-Hodgkin - Childhood
• Lymphoma - Non-Hodgkin
• Multiple Myeloma
• Myelodysplastic Syndromes - MDS

Each guide provides information on:

• Overview
• Medical Illustrations
• Risk Factors
• Prevention
• Symptoms
• Diagnosis
• Staging With Illustrations
• Treatment
• Clinical Trials Resources
• Side Effects, After Treatment
• Current Research
• Questions to Ask the Doctor
• Patient Information Resources

Malignant lymphomas provide model strategies for cancer management. The sequential issues of sophisticated diagnostic and staging procedures, definition of therapeutic goals and integration of multimodality management are all present. These guidelines emphasise the need for appropriate biopsy techniques to allow accurate diagnosis and subtyping according to the WHO scheme. Technical advances, particularly in molecular biology, will further refine diagnosis and generate prognostic information. These advances will allow treatment to be more tailored to individuals. In all types of lymphoma staging, using appropriate radiological techniques further refines prognosis and treatment selection. Emerging data from PET scanning offer additional promise.

Treatment across the spectrum of the lymphomas requires careful consideration of the integration of chemotherapy and/or radiotherapy. The availability of products of biotechnology (monoclonal antibodies and growth factors) in conjunction with chemotherapy offers improvements in treatment outcome. The entry of patients into appropriate clinical trials is recommended to improve evidence-based management policies. The diagnostic and staging procedures define treatment decisions with either curative or palliative intent, depending on the subtype and stage of the lymphoma.

The guidelines stress the need for the development of multimodality teams to guide the patient‘s journey from diagnosis through what are sometimes complex and difficult treatments.

Each chapter can be downloaded separately as a PDF file.

A guide to assist general practitioners to recognise the symptoms of lymphoma and refer patients for appropriate treatment.

Information about the genetic risk of chronic lymphocytic leukaemia and methods of preventing the development of the disease.

Six genetic variants, on chromosomes 2, 6, 11, 15 and 19, have been associated with increased risk of developing CLL. The deCODEme Complete Scan identifies these variants and provides an interpretation of the associated risk of CLL for individuals of European descent. At the current time, risk information for other ethnicities is not available for these variants.

This case study recounts the experience of Ellie, a 4-year-old female diagnosed with ALL. This case study aims to facilitate the development of competencies that reflect the role of the Specialist Cancer Nurse (SCN) in managing disease and treatment related care for the child and family affected by ALL across the cancer journey.

The case study contains three sections:

• Find the condition early
• Have the best treatment and support during active treatment
• Have the best treatment and support between and after active treatment.

This case study recounts the experience of Arthur, a 78-year-old male diagnosed with non-Hodgkin‘s Lymphoma (NHL). The case study focuses on the Specialist Cancer Nurse‘s role in the provision and coordination of care for people with NHL, as well as exploring issues associated with diagnosis of cancer in the older person.

The case study contains five sections:

• Reduce risk
• Find the condition early
• Have the best treatment and support during active treatment
• Have the best treatment and support between and after active treatment
• Have the best care at the end of life.

This primary care haematology module includes resources and information specific to leukaemias, lymphomas, myelomas and other blood cancers, treatments and side effect management, clincial tools, an opioid conversion calculator and safe handling of cytotoxics.

Free registration is required to access the site.

Treatment decision tools to help patients make an informed decision about their treatment for the following cancers:

• Hodgkin Lymphoma
• Leukemia - Adult ALL (lymphoblastic)
• Leukemia - Adult AML (myelogenous)
• Leukemia - Adult CML (myelogenous)
• Multiple Myeloma
• Non-Hodgkin's Lymphoma

Using these tools, patients can access a detailed analysis of their specific condition, uncover a statistical breakdown of treatment types, and pinpoint the exact topics to discuss with their doctor.

Consumer targeted overview of haematological cancers including:

Information is provided regarding risk factors, signs and symptoms, diagnosis, treatment and links to a patient resource centre.

HemOnc Today strives to be the global, definitive information source for oncology and hematology professionals by delivering timely, accurate, authoritative and balanced reports on clinical issues, socioeconomic topics and industry developments relating to Hematologic Malignancies, as well as presenting clinically relevant information on medical therapies for the benefit of the patient.

Diagnosing lymphoma is often challenging as patients may present with a varied range of clinical features. To assist GPs, this decision support tool was prepared by the Leukaemia Foundation’s Medical and Scientific Advisory Committee.

The Leukaemia Foundation has developed a tool to assist GP’s in the diagnosis of myeloma.

Myeloma (also called multiple myeloma) is the most rapidly increasing blood cancer in Australia. The diagnosis of myeloma can be challenging as it is reasonably rare with approximately 1500 people diagnosed each year in Australia. A GP may only encounter a few patients in their career and this may lead to limited awareness of the condition.

The Leukemia & Lymphoma Society (LLS) is the world's largest voluntary health organization dedicated to funding blood cancer research, education and patient services.

The site provides information about haematological cancers including leukemia, lymphoma, Hodgkin's disease and myeloma and the work of the society to find a cure and develop treatments.

The site also includes information and resources for patients and disease information. 

Information about the work of the Lymphoma Research Foundation which works to develop treatments for lymphomas to extend the lives of patients.

The site also includes information and resources for patients, that can be ordered or downloaded from the site, including:

Childhood Non Hodgkin lymphoma

CLL/SLL

Hodgkin lymphoma

Non-Hodgkin lymphoma

Providing relevant, high quality and up-to-date information, MedConnect is a gateway to leading local and international medical news, research, events and resources to allow health care professionals to stay connected to the most important developments in medicine.

The haematological cancers page includes information about leukaemias, lymphomas and myelomas and features the latest news, research, drugs, podcasts, videos, articles, conferences and events.  

Users can sign up for free to receive daily news feeds and journal summaries about their specialist topic.

A series of infosheets, booklets and other information published by the Myeloma Foundation of Australia to inform both health professionals and consumers about the latest developments in the management and treatment of myeloma.

The Myeloma Nurse Learning Programme© is an innovative online learning course specifically designed for haematology and oncology nurses with a particular interest in myeloma. Whilst UK based, it is also extremely relevant to Australian nurses. It has been designed to inform and challenge nurses over a series of ten self-learning modules, which include reflective activities, 3D animations and video clips from myeloma specialists and patients. At the end of each module there is a self assessment quiz, and the programme is assessed by four formal examination assessments which should be completed at the end of the programme.

The Myeloma Nurse Learning Programme© is:

• Endorsed by Royal College of Nursing Australia (RCNA) for CNE points: upon completion of the programme, nurses can claim 170 points towards their continuing education requirement.

• Free and available to all nurses with an interest in myeloma

• Flexible to fit around nurses’ busy schedules

• Credit-rated by Edinburgh Napier University

• Interactive and complete with 3D animations and online media

• Up-to-date with relevant evidence and best practice to support nurses in their work

• Reviewed by doctor and nurse specialists in myeloma and uses the most up to date research and best practice to inform it.

The program can be ordered from Myeloma Foundation of Australia: http://www.myeloma.org.au/ or Myeloma Foundation of UK: http://www.magicfornurses.co.uk/

Downloadable clinical practice guidelines developed and endorsed by NCCN for:

• Acute Myeloid Leukemia
• Chronic Myelogenous Leukemia
• Hodgkin Lymphoma
• Multiple Myeloma
• Non-Hodgkin's Lymphomas
• Waldenström's Macroglobulinemia / Lymphoplasmacytic Lymphoma

A range of guidelines and resources relating to carcinoma of haematological cancers. including:

Leukemia

• Acute Lymphoblastic Leukemia (ALL)
• Acute Myeloid Leukemia (AML)
• Chronic Lymphocytic Leukemia (CLL)
• Chronic Myelogenous Leukemia (CML)
• Hairy Cell Leukaemia
  

  Lymphoma

  • AIDS-Related
  • Hodgkin
  • Non-Hodgkin
  • Primary Central Nervous System (CNS)

  Myeloma

  • Myeloma, Multiple
  • Myelodysplastic Syndromes
  • Myelodysplastic/Myeloproliferative Neoplasms
  • Chronic Myeloproliferative Disorders

  Information provided includes:

  • information about prevention, genetics and causes
  • screening and testing unformation about methods of cancer detection including new imaging technologies, tumor markers, and biopsy procedures
  • Information about treatment, including surgery, chemotherapy, radiation therapy, immunotherapy, and vaccine therapy
  • statistics related to cancer incidence, mortality, and survival
  • research
  • information and current news about clinical trials and trial-related data

A library of downloadable clinical practice guidelines developed in the UK and internationally relating to the diagnosis, treatment and management of haematological cancers, including:

• Chronic leukaemia
• Acute leukaemia
• Myeloma
• Non-Hodgkins lymphoma
• Hodgkins disease

Comprehensive information regarding the following Haematological Cancers:

• Leukemia-- Acute Lymphocytic Leukemia (ALL)
• Leukemia-- Acute Myelogenous Leukemia (AML)
• Leukemia: The Basics
• Lymphoma: Non-Hodgkin's Disease
• Lymphomas: Hodgkin's Lymphoma (Childhood)
• Lymphomas: Non-Hodgkin's Lymphoma (Childhood)
• Myelodysplastic Syndromes (MDS)
• Myelomas
• Myeloproliferative Disorders
• AIDS-related Lymphoma
• Hairy Cell Leukemia
• Hodgkin's Disease
• Cutaneous T-Cell Lymphoma/Mycosis Fungoides
  

This patient management framework is a guide to the optimal care management of patients with Acute Myeloid Leukaemia. It is intended to improve patient outcomes by facilitating consistent care based on evidence and best practice and sets out the key requirements for the provision of optimal care which need to be considered at each step of the care pathway.

In contrast to clinical practice guidelines that guide appropriate practice and decision making, the patient management frameworks provide a guide to the patient journey to ensure patients with cancer and their families receive optimal care and support.

This patient management framework is a guide to the optimal care management of patients with Intermediate grade Non-Hodgkin Lymphoma. It is intended to improve patient outcomes by facilitating consistent care based on evidence and best practice and sets out the key requirements for the provision of optimal care which need to be considered at each step of the care pathway.

In contrast to clinical practice guidelines that guide appropriate practice and decision making, the patient management frameworks provide a guide to the patient journey to ensure patients with cancer and their families receive optimal care and support.

Information about radiation therapy treatment options for patients lymphomas, including downloadable PDF fact sheets including information about possible side effects of treatment.

Established in Queensland in 1975, the Leukaemia Foundation is the only national organisation dedicated to the care and cure of patients and families living with:

• leukaemias
• lymphomas
• myeloma
• related blood disorders including myelodysplastic syndromes, myeloproliferate disorders (PRV, ET, MF), waldenstroms, amyloidosis and aplastic anaemia.

The Leukaemia Foundation works closely with health professionals to provide a continuum of care for patients and their families as well as fund innovative Australian research, fellowships and scholarships.

Information, patient guides, news and latest research for health professionals is included for each of the diseases.

Information about the work of the Multiple Myeloma Research Foundation which works to develop treatments for multiple myeloma to extend the lives of patients.

The site also includes information and resources for patients, including those who have been newly diagnosed, those commencing treatment and those facing a relapse.

This Profiler tool includes information on head and neck cancers of the oral cavity, oropharynx and larynx (voice box). Treatment for head and neck cancers located in the ethmoid or maxillary sinus, hypopharynx, or nasopharynx areas is not included.

The Head and Neck Cancers Profiler treatment decision support tool helps you understand how your diagnosis, test results, and medical history affect your treatment options. 

The free Treatment Options Report will include descriptions of treatments, side effects, and questions to ask your doctor…customized for your unique diagnosis.

Mouth cancer is becoming more common, especially in younger people. The main risk factors are tobacco and excessive alcohol consumption, but some people with mouth cancer have been exposed to neither.

This module assists you to recognise the symptoms of mouth cancer, such as white or red patches on the oral mucosa, so that the patient can be referred to a specialist.

Mouth cancer diagnosed early has an 80% survival rate, whereas disease diagnosed late has a prognosis less than 50%.

A range of clinical practice tools and resources including guidelines, slides and patient information regarding head and neck cancers, including a  patient guide for larynx preservation.

ASCO's Head and Neck Cancer Portal offers head and neck cancer specific resources including the latest information from:

• ASCO's Virtual Meeting
• The Journal of Clinical Oncology
• Head and Neck Cancer Clinical Practice Guidelines
• Meeting abstracts
• Educational Book manuscripts
• ASCO Daily News.

Information for people with gyanecological cancers and their families and friends; including information and downloadable PDF brochures, Understanding Head and Neck cancers.

Comprehenisve oncologist approved information about head and neck cancers. A guide is also available for:

• Esophageal Cancer
• Eye Cancer
• Nasal Cavity and Paranasal Sinus Cancer
• Oral and Oropharyngeal Cancer
• Salivary Gland Cancer
• Eyelid Cancer

Each guide provides information on:

• Overview
• Medical Illustrations
• Risk Factors
• Prevention
• Symptoms
• Diagnosis
• Staging With Illustrations
• Treatment
• Clinical Trials Resources
• Side Effects, After Treatment
• Current Research
• Questions to Ask the Doctor
• Patient Information Resources

This case study recounts the experience of Mrs Li, a 55-year-old female diagnosed with head and neck cancer. This case study aims aim to facilitate the development of competencies that reflect the role of the Specialist Cancer Nurse (SCN) in ensuring a coordinated approach to care planning, implementation and evaluation across the cancer journey for people affected by head and neck cancer.

The case study contains five sections:

• Reduce risk; Find the condition early
• Have the best treatment and support during active treatment
• Have the best treatment and support between and after active treatment
• Have the best care at the end of life.

This case study recounts the experience of Burt, a 68-year-old male diagnosed with oesophageal cancer. This case study aims to facilitate the development of competencies that reflect the role of the Specialist Cancer Nurse (SCN) in the delivery of evidence-based supportive care, including provision of information and education for people affected by oesophageal cancer.

The case study contains four sections:

• Reduce risk; Have the best treatment and support during active treatment
• Have the best treatment and support between and after active treatment
• Have the best care at the end of life.

This primary care module includes resources and information specific to head and neck cancers, treatments and side effect management, clincial tools, an opioid conversion calculator and safe handling of cytotoxics.

Free registration is required to access the site.

The purpose of these guidelines is to provide the multidisciplinary team of health professionals with a summary of evidence-based clinical questions related to the nutrition management of adult patients with head and neck cancer.

Head and neck cancer is the fifth most common cancer worldwide. this population is often nutritionally compromised to some degree from the onset, with malnutrition rates reported between 30-50%. The causes of malnutrition are multifactorial including lifestyle factors of tobacco and alcohol use and baseline dietary intake; as well as tumour location and burden, and side effects of multi-modal treatment regimens. Furthermore, malnutrition results in impaired wound healing, reduced immunocompetence, a decreased tolerance to treatment, resulting in undesired treatment breaks and unplanned hospital admissions. Consequently nutrition support plays a crucial role in the provision of best practice care to this population.

The website provides a forum for public comment and debate regarding the guidelines.

Consumer targeted overview of head and neck cancers including information regarding risk factors, signs and symptoms, diagnosis, treatment and links to a patient resource centre.

Also available for: